Immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and PD ligand 1 (PD-L1) monoclonal antibodies, have shown enormous survival benefits among patients with NSCLC (2). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.